{
    "nctId": "NCT01910844",
    "briefTitle": "Phase II Pilot Study Assessing Efficacy of a Cisplatin - M\u00e9tronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes",
    "officialTitle": "N/A",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3,
    "primaryOutcomeMeasure": "Response rate of cisplatine - metronomic cyclophosphamide treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Performance status \\< 2,\n* Patient with metastatic breast cancer stade IV triple negative histologically confirmed\n* Measurable or not disease but radiologically evaluable (RECIST 1.1),\n* Negative Hormonal Receptors (Estrogens and/or Progesterone),\n* HER-2 negative (Score 0 or 1 by Immunochemistry (IHC), negative FISH if score IHC 2),\n* Patient exposed to anthracyclines and/or taxanes in neo-adjuvant or adjuvant setting,\n* Patient with a progression and for whom anthracyclines and/or taxanes treatment cannot be delivered and according to a resistance defined as :\n* In the last 12 months after the last dose of taxanes or anthracyclines in adjuvant or neoadjuvant setting or,\n* During or after a first metastatic chemtotherapy line and where taxanes and anthracyclines cannot be delivered according to :\n* either a secondary resistance after an initial response to chemotherapy but a relapse observed either during the treatment or in the 4 months after the end of chemotherapy.\n* either a sensitivity to treatment defined by a relapse after more than 4 months after the first chemotherapy metastatic line,\n* either intolerance to anthracyclines (doxorubicin 240-400 mg/m\u00b2 ou equivalent to doxorubicin (epirubicin) 300-550mg/m\u00b2)\n* Patient non previously treated by platinum salts,\n* Hematological Functions: Neutrophiles \u2265 1,5.109/L, Platelets \u2265 100.109/L, Leucocytes \\> 3 000/mm3, Hb \\> 9g/dL, Hepatic Functions : total Bilirubin \u2264 1,5 time upper normal value (UNV), ASAT \u2264 2 ,5 time UNV, ALAT \u2264 2,5 time UNV, Alkaline Phosphatase \u2264 2,5 time UNV (\\< 5 time UNV if case of hepatic metastasis), Renal Functions: Serum Creatinine \u2264 1,5 time UNV (and if value \\> 1,5 time UNV, so Clearance \u2265 60 mL/min) or Clearance \u2265 40 mL/min in case of RMI,\n* Patient signed the consent study form,\n* Patient affiliated to a social security regimen (law of 9 August 2004).\n\nExclusion Criteria:\n\n* Male Patients,\n* Unknown hormonal Receptors\n* Positive HER-2 (Score 3 in IHC or positive FISH)\n* Pregnant or breastfeeding patient, or in age of pregnancy or predicting to be pregnant in the 6 months after the end of treatment,\n* Patient not using contraceptive treatment during the treatment or after the 6 months after the end of treatment,\n* Patient is a ward,\n* Patient suffering from a non compatible disease with the enrollment in the study,\n* Cardiac, renal, medullar, respiratory or hepatic insufficiency, clinically significant cardiovascular disease (including myocardiac infarct, unstable angina, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia) \\< 1 year before the study enrollment or randomisation,\n* Patient with pulmonary lymphangitis or symptomatic pleural effusion (grade\u22652), meningeal known carcinoma or symptoms of cerebromeningeal invasion, brain metastases unless treatment and stability for at least 4 weeks (no steroids or anti-convulsive).\n* Uncontrolled diabetes,\n* Psychiatric or neurological significant abnormality,\n* Peripheric Neuropathy \\> grade 2,\n* Antecedent of hypersensibility to one of study treatment or one of used excipients,\n* Urinary tract infection or acute hemorrhagic cystitis in progress\n* Concomitant treatment with a medicine containing phenytoin or medication received in the context of a trial, or participation in another therapeutic clinical trial within \\<30 days prior treatment with chemotherapy.\n* Geographically unstable patient in the next 6 months or remaining distance to the treatment center making it difficult to follow in the study,\n* Known history of abuse of narcotic or other drug or alcohol\n* History of surgery within 28 days before the start of treatment,\n* Patient unwilling or unable to comply with the requirements of the study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}